Nomogram prediction of survival in patients with brain metastases from hepatocellular carcinoma treated with whole-brain radiotherapy: a multicenter retrospective study

被引:0
|
作者
Younghee Park
Kyung Su Kim
Kyubo Kim
Eui Kyu Chie
Jin Ho Kim
Jae-Sung Kim
Tae Hyun Kim
Dae Yong Kim
Won Il Jang
Mi-Sook Kim
Tae Ryool Koo
Ah Ram Chang
机构
[1] Soonchunhyang University Seoul Hospital,Department of Radiation Oncology
[2] Seoul National University College of Medicine,Department of Radiation Oncology
[3] Seoul National University Bundang Hospital,Department of Radiation Oncology, Seoul National University College of Medicine
[4] National Cancer Center,Center for Proton Therapy, Research Institute and Hospital
[5] Korea Institute of Radiological & Medical Sciences,Department of Radiation Oncology
来源
Journal of Neuro-Oncology | 2015年 / 125卷
关键词
Brain metastasis; Hepatocellular carcinoma; Prognostic factor; Nomogram;
D O I
暂无
中图分类号
学科分类号
摘要
The incidence of brain metastasis from hepatocellular carcinoma (HCC) is increasing because of the improved survival outcome of HCC patients, but the prognosis of these patients is extremely poor. HCC patients with brain metastasis were investigated to identify their prognostic factors for overall survival. Patients with brain metastasis from HCC who had been treated with whole-brain radiotherapy (WBRT) in five hospitals were enrolled in the study. The medical records of the patients were reviewed, and the clinical factors were analyzed to identify the prognostic factors for overall survival. Of the total of 97 patients who were enrolled in the study, 83 were male and the median age at the brain metastases was 56.6 years. Motor weakness (43.3 %) and headache (41.2 %) were common presenting symptoms. The median AFP level was 4180 ng/ml, and 81 patients were assessed as belonging to Child-Pugh classification A upon the diagnosis of brain metastasis. WBRT alone in 71 patients, surgery or radiosurgery combined with WBRT as the adjuvant setting in 18 patients, and WBRT as salvage treatment in 8 patients were performed. The median overall survival of the patients was 3.5 months. In the multivariate analysis, the ECOG performance status (PS), Child-Pugh classification, AFP, and treatment aim showed significant association with the overall survival of the patients. Based on these factors, a nomogram predicting the prognosis was developed. The concordance index of the nomogram was 0.74, and the prediction was well calibrated. In conclusion, the survival outcome of patients with brain metastasis from HCC can be predicted with the nomogram constructed from the ECOG PS, Child-Pugh classification, AFP, and treatment aim.
引用
收藏
页码:377 / 383
页数:6
相关论文
共 50 条
  • [31] Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery
    Nieder, Carsten
    Mannsaker, Bard
    Yobuta, Rosalba
    IN VIVO, 2021, 35 (03): : 1569 - 1572
  • [32] Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases
    Xie, Xue-Yi
    Peng, Hong-Hua
    Zhang, Xi
    Pan, Yu-Liang
    Zhang, Zhen
    Cao, Pei-Guo
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [33] Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases
    Xue-Yi Xie
    Hong-Hua Peng
    Xi Zhang
    Yu-Liang Pan
    Zhen Zhang
    Pei-Guo Cao
    Radiation Oncology, 17
  • [34] Survival time and prognostic factors after whole-brain radiotherapy of brain metastases from of breast cancer
    Okada, Yukinori
    Kobayashi, Mariko
    Shinozaki, Mio
    Abe, Tatsuyuki
    Kanemaki, Yoshihide
    Nakamura, Naoki
    Kojima, Yasuyuki
    ACTA RADIOLOGICA OPEN, 2020, 9 (07)
  • [35] Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors
    Kouvaris, John R.
    Miliadou, Anthi
    Kouloulias, Vassilis E.
    Kolokouris, Dimitrios
    Balafouta, Myrsini J.
    Papacharalampous, Xenofon N.
    Vlahos, Lambros J.
    ONKOLOGIE, 2007, 30 (07): : 361 - 366
  • [36] Should patients with melanoma brain metastases receive adjuvant whole-brain radiotherapy?
    Fogarty, Gerald B.
    Hong, Angela
    Thompson, John F.
    LANCET ONCOLOGY, 2015, 16 (05): : E195 - E196
  • [37] Whole-brain radiotherapy and chemotherapy in the treatment of patients with breast cancer and brain metastases
    Xu, Kai
    Huang, Yong
    Yao, Junzhong
    Xu, Zhong
    He, Xiaofei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2021, 14 (02): : 1250 - 1257
  • [38] SHORTER-COURSE WHOLE-BRAIN RADIOTHERAPY FOR BRAIN METASTASES IN ELDERLY PATIENTS
    Rades, Dirk
    Evers, Jasmin N.
    Veninga, Theo
    Stalpers, Lukas J. A.
    Lohynska, Radka
    Schild, Steven E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04): : E469 - E473
  • [39] The Results of Whole-brain Radiotherapy for Elderly Patients With Brain Metastases from Urinary Bladder Cancer
    Rades, Dirk
    Trang Nguyen
    Schild, Steven E.
    IN VIVO, 2020, 34 (03): : 1317 - 1320
  • [40] Dose Escalation in Patients Receiving Whole-Brain Radiotherapy for Brain Metastases from Colorectal Cancer
    Heisterkamp, Christine
    Haatanen, Tiina
    Schild, Steven E.
    Rades, Dirk
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (02) : 70 - 75